The sustained granulopoietic effect of progenipoietin encapsulated in multivesicular liposomes

详细信息    查看全文

• 作者：Ramprasad ; Mysore P. ; Amini ; Arjang ; Kararli ; Tugrul ; Katre ; Nandini V.
• 关键词：Progenipoietin ; Hematopoietic growth factors ; Multivesicular liposome ; DepoFoam ; Sustained granulopoiesis ; G-CSF
• 刊名：International Journal of Pharmaceutics
• 出版年：2003
• 出版时间：August 11, 2003
• 年：2003
• 卷：261
• 期：1-2
• 页码：93-103
• 全文大小：313 K

文摘

Progenipoietin (ProGP), a dual receptor agonist of fetal liver tyrosine kinase-3 (flt3) and granulocyte colony-stimulating factor (G-CSF) receptors, has been shown to significantly enhance production of both polymorphonuclear leukocytes and dendritic cells (DCs) in the peripheral blood and spleen of mice, when administered as daily s.c. injections for about 10 days. Here, we have successfully designed a sustained-delivery formulation for this novel chimeric protein using multivesicular liposomes (DepoFoam), and studied the effects of changing both the triglyceride and phospholipid composition of the lipid matrix to modulate its delivery profile. Encapsulation of ProGP in these particles led to retention of its structural integrity, and maintenance of its biological activity in vivo. Administration of a single s.c. dose of 1mg/kg of an optimized DepoProGP formulation in rats, led to significant elevation of absolute neutrophil counts (ANC) that were maintained at levels >10,000μl⁻¹ for 9–11 days, in a reproducible manner. In contrast, administration of the unencapsulated ProGP at the same dose, resulted in elevation of neutrophils by day 1, followed by a quick decline to base line levels by day 3. These data suggest the possibility of administering a single dose of DepoFoam-encapsulated ProGP to improve hematopoietic recovery time after chemotherapy, and for other indications that require multiple daily doses of ProGP.